Evolution of the Average Target: Autolus Therapeutics plc

Evolution of the Target Price: Autolus Therapeutics plc

Changes in Analyst Recommendations: Autolus Therapeutics plc

ee6ae672033a16f8677885dfb2f765.fe87AB7q0w6iOfnMuLi2U6YZfIULt1ecXacRL6CeiXs.J9dKV0qegj7oTamIid7PNcRLDcx-4SXRDZEoXZH20Qsou3JFaaa1aY9SrA~c0921b45b182ab6086460487910574d8
03-31 Mizuho Cuts Price Target on Autolus Therapeutics to $10 From $12, Keeps Outperform Rating MT
01-13 Truist Adjusts Price Target on Autolus Therapeutics to $8 From $10, Maintains Buy Rating MT
01-13 Truist Cuts Price Target on Autolus Therapeutics to $8 From $10, Keeps Buy Rating MT
25-03-31 Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating MT
24-11-18 Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7 MT
24-11-15 Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13 MT
24-03-18 Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating MT
24-02-12 Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating MT
24-01-22 Needham Adjusts Autolus Therapeutics' Price Target to $8 From $7, Maintains Buy Rating MT
23-12-13 Goldman Sachs Raises Price Target on Autolus Therapeutics to $4.80 From $3.20, Maintains Neutral Rating MT
23-11-09 Deutsche Bank Initiates Coverage on Autolus Therapeutics With Buy Rating, $10 Price Target MT
23-08-17 Truist Securities Adjusts Price Target on Autolus Therapeutics to $9 From $6, Maintains Buy Rating MT
23-05-05 Wells Fargo Adjusts Price Target on Autolus Therapeutics to $6 From $8, Maintains Overweight Rating MT
23-03-27 Wells Fargo Assumes Autolus Therapeutics at Overweight With $8 Price Target MT
23-03-08 Mizuho Adjusts Price Target on Autolus Therapeutics to $12 From $18, Maintains Buy Rating MT
22-12-09 Needham Lowers Price Target on Autolus Therapeutics to $7 From $12, Maintains Buy Rating MT
22-08-23 Truist Securities Trims Autolus Therapeutics' Price Target to $10 From $11, Maintains Buy Rating MT
22-06-14 Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating MT
21-12-20 HC Wainwright Adjusts Autolus Therapeutics' Price Target to $11 From $13, Reiterates Buy Rating MT
21-08-24 AUTOLUS THERAPEUTICS : Goldman Sachs Adjusts Price Target on Autolus Therapeutics to $5.50 From $9.50, Maintains Neutral Rating MT
21-06-14 AUTOLUS THERAPEUTICS : Jefferies Lifts Autolus Therapeutics to Buy From Hold, Price Target to $12 From $6 MT
21-05-06 AUTOLUS THERAPEUTICS : Needham & Co Adjusts Autolus Therapeutics PT to $21 From $26, Maintains Buy Rating MT
21-03-10 AUTOLUS THERAPEUTICS : Redburn Downgrades Autolus Therapeutics to Neutral from Buy MT
21-01-29 AUTOLUS THERAPEUTICS : JPMorgan Downgrades Autolus Therapeutics to Neutral From Overweight, Adjusts Price Target to $9 From $24 MT
21-01-07 AUTOLUS THERAPEUTICS : HC Wainwright Adjusts Autolus Therapeutics' Price Target to $13 From $19, Keeps at Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+441.14%
+27.36%
+10.96%
+44.72%
+14.36%
+1.93%
-42.52%
-4.78%
+33.59%
+0.47%
Average +52.72%
Weighted average by Cap. +13.30%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.580USD
Average target price
8.550USD
Spread / Average Target
+441.14%
High Price Target
11.00USD
Spread / Highest target
+596.20%
Low Price Target
5.000USD
Spread / Lowest Target
+216.46%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Mizuho Securities
Truist Securities
Goldman Sachs
Redburn Atlantic
Needham & Co.
Deutsche Bank Securities
Wells Fargo Securities
HC Wainwright
Jefferies & Co.
Redburn
J.P. Morgan Chase
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.580USD
Average target price
8.550USD
Spread / Average Target
+441.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock
  4. Consensus Autolus Therapeutics plc